Using Neural Network Activity Readouts in Human iPSC-derived Neuron/Glia Co-Cultures for in Vitro Neurotoxicity Assessment

About the Speaker

As the Head of Neuroscience and Co-founder, Dr. Daniel Haag drives the scientific direction of NeuCyte Inc. and leads the development of novel human neural in vitro platforms for neurotoxicity assessment and drug discovery. After graduating from the Technical University of Darmstadt, he prepared his doctoral thesis at the German Cancer Research Center and the University of Heidelberg studying genetic drivers in brain tumors. During his postdoctoral appointment at Stanford University, he became an expert in neural differentiation and direct reprogramming of iPS cells as well as genome engineering and in vitro modeling of CNS disorders.